Avadel Pharmaceuticals AVDL Stock
8.75 USD
{{ price }}
-0.228055%
{{change_pct}}%
SECTOR
Healthcare
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
845.51M USD
LOW - HIGH [24H]
8.63
-
8.82 USD
VOLUME [24H]
897.11K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.51 USD
Avadel Pharmaceuticals Price Chart
Avadel Pharmaceuticals AVDL Financial and Trading Overview
| Avadel Pharmaceuticals stock price | 8.75 USD |
| Previous Close | 15.06 USD |
| Open | 15 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 800 |
| Day's Range | 14.74 - 15.07 USD |
| 52 Week Range | 2.26 - 15.82 USD |
| Volume | 455.09K USD |
| Avg. Volume | 938.28K USD |
| Market Cap | 1.14B USD |
| Beta (5Y Monthly) | 1.427112 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.51 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.06 USD |
AVDL Valuation Measures
| Enterprise Value | 1.15B USD |
| Trailing P/E | N/A |
| Forward P/E | -64.347824 |
| PEG Ratio (5 yr expected) | -0.67 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -12.361 |
Trading Information
Avadel Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.427112 |
| 52-Week Change | 532.47% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15.82 USD |
| 52 Week Low | 2.26 USD |
| 50-Day Moving Average | 12.85 USD |
| 200-Day Moving Average | 8.72 USD |
AVDL Share Statistics
| Avg. Volume (3 month) | 938.28K USD |
| Avg. Daily Volume (10-Days) | 504.66K USD |
| Shares Outstanding | 76.77M |
| Float | 57.2M |
| Short Ratio | 3.21 |
| % Held by Insiders | 5.21% |
| % Held by Institutions | 45.16% |
| Shares Short | 4.05M |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 5.26% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.77% |
| Return on Equity (ttm) | -1662.065% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -93066000 USD |
| Net Income Avi to Common (ttm) | -141824000 USD |
| Diluted EPS (ttm) | -2.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 100.92M USD |
| Total Cash Per Share (mrq) | 1.32 USD |
| Total Debt (mrq) | 115.16M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.379 |
| Book Value Per Share (mrq) | -0.592 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -66492000 USD |
| Levered Free Cash Flow (ttm) | 16.72M USD |
Profile of Avadel Pharmaceuticals
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | 10 Earlsfort Terrace |
| ZIP | 2 |
| Phone | 353 1 901 5201 |
| Website | https://www.avadel.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 41 |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Q&A For Avadel Pharmaceuticals Stock
What is a current AVDL stock price?
Avadel Pharmaceuticals AVDL stock price today per share is 8.75 USD.
How to purchase Avadel Pharmaceuticals stock?
You can buy AVDL shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Avadel Pharmaceuticals?
The stock symbol or ticker of Avadel Pharmaceuticals is AVDL.
Which industry does the Avadel Pharmaceuticals company belong to?
The Avadel Pharmaceuticals industry is Drug Manufacturers-Specialty & Generic.
How many shares does Avadel Pharmaceuticals have in circulation?
The max supply of Avadel Pharmaceuticals shares is 96.63M.
What is Avadel Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Avadel Pharmaceuticals PE Ratio is now.
What was Avadel Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Avadel Pharmaceuticals EPS is -0.51 USD over the trailing 12 months.
Which sector does the Avadel Pharmaceuticals company belong to?
The Avadel Pharmaceuticals sector is Healthcare.
Avadel Pharmaceuticals AVDL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.58B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.58B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1854.61 USD — |
+0.81
|
— — | 1835.2 USD — | 1871.93 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4184.77 USD — |
+1.29
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
- {{ link.label }} {{link}}